The same group also showed that tumor growth was reduced by single targeting of ERBB2 in cetuximab-resistant, quadruple (i.e., KRAS, NRAS, BRAF, and PIK3CA) wt CRC patient derived xenografts with ERBB2 mutations. This evidence concerns the gene BRAF and colorectal carcinoma.